Two diagnostics-led companies reported preliminary Q4 gains driven by testing volume. Tempus said preliminary Q4 revenue was about $367 million—an 83% year‑over‑year increase—attributing growth mainly to testing and data licensing; the company flagged diagnostics revenue of roughly $266 million and a large contract backlog ahead of its JP Morgan presentation. Guardant Health reported preliminary Q4 revenue of ~$280 million, up 39%, citing a sharp rise in both oncology test volumes and Shield screening tests (the latter grew nearly fivefold year over year). The results underscore growing demand for molecular testing across oncology and population screening. Both firms highlighted volume expansion and data partnerships as revenue levers; investors will watch whether higher testing throughput converts to sustained margins and scalable commercial contracts.